Fairvalue-Calculator Fairvalue-Calculator
EN DE

MediciNova, Inc (MNOV) Fair Value & Analysis

Healthcare · US · Market cap $65.0M

Price$1.33
Fair Value$0.5500
Upside-58.6%
Quality95/100
Evidence: Low Range $0.3600 – $0.6900

Fair value as of: Jun 25, 2026

Analysis

MediciNova, Inc (MNOV) currently trades at $1.33, while our model-based Fair Value estimate is $0.5500 — implying the stock looks roughly 58.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is MediciNova, Inc (MNOV) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.5500 versus a price of $1.33 — about −59% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MNOV?
Our 21-model fair value for MediciNova, Inc is $0.5500 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.33.
What is the quality score of MNOV?
MediciNova, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.